An Evaluation of Biometric Monitoring Technologies for Vital Signs in the Era of COVID‐19

• Published in: Clinical and translational science Vol. 13; no. 6; pp. 1034 - 1044
• Main Authors: Manta, Christine, Jain, Sneha S., Coravos, Andrea, Mendelsohn, Dena, Izmailova, Elena S.
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.11.2020; John Wiley and Sons Inc
• Subjects: Accuracy; Biometrics; Biometry - methods; Blood pressure; Body Temperature; Coronaviruses; COVID-19; COVID-19 - physiopathology; Data Collection; Engineering; Heart rate; Human subjects; Humans; Hypertension; Medical equipment; Medical technology; Oxygen - blood; Oxygen saturation; Pandemics; Patients; Pulse oximetry; Respiration; Review; Reviews; SARS-CoV-2; Sensors; Severe acute respiratory syndrome coronavirus 2; Telemedicine - methods; Usability; Vital Signs; United States > US
• ISSN: 1752-8054; 1752-8062; 1752-8062
• DOI: 10.1111/cts.12874

The novel coronavirus disease 2019 (COVID‐19) global pandemic has shifted how many patients receive outpatient care. Telehealth and remote monitoring have become more prevalent, and measurements taken in a patient’s home using biometric monitoring technologies (BioMeTs) offer convenient opportunities to collect vital sign data. Healthcare providers may lack prior experience using BioMeTs in remote patient care, and, therefore, may be unfamiliar with the many versions of BioMeTs, novel data collection protocols, and context of the values collected. To make informed patient care decisions based on the biometric data collected remotely, it is important to understand the engineering solutions embedded in the products, data collection protocols, form factors (physical size and shape), data quality considerations, and availability of validation information. This article provides an overview of BioMeTs available for collecting vital signs (temperature, heart rate, blood pressure, oxygen saturation, and respiratory rate) and discusses the strengths and limitations of continuous monitoring. We provide considerations for remote data collection and sources of validation information to guide BioMeT use in the era of COVID‐19 and beyond.